RxDoctor Payments Data

Monique Rash, NP

Family · Blacksburg, VANPI 1689927691

Payments from drug & device makers

$1,052in general payments, 2019–2025

Across 57 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$372
  • Boehringer Ingelheim$117
  • Neurocrine Biosciences, Inc.$93
  • GSK$92
  • Corium, LLC$71
  • E.r. Squibb & Sons, L.L.C.$66
  • plus $240 from 8 others

What the payments were for

  • Food & beverage$1,052100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,052 in reported general payments places this provider in the 70th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$11,652
Medicare patients
44
Services billed
224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole35$104,670
Risperdal ConstaRisperidone Microspheres17$38,216
Wellbutrin XlBupropion Hcl12$32,534
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$31,074
VraylarCariprazine Hcl22$30,710
OzempicSemaglutide16$20,998
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl166$18,398
TrintellixVortioxetine Hydrobromide28$14,953
Aripiprazole136$13,356
Paliperidone ErPaliperidone16$7,373
SuboxoneBuprenorphine Hcl/Naloxone Hcl16$6,489
Fluvoxamine Maleate ErFluvoxamine Maleate15$5,710
Clozapine82$5,328
Breo ElliptaFluticasone/Vilanterol12$4,820
Haloperidol104$4,041

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonRisperdal Consta$27$38,21617 claims
GSKTrelegy Ellipta, Breo Ellipta$92$35,89456 claims
Indivior Inc.Suboxone$44$6,48916 claims
Lilly USA, LLCOlanzapine$48$3,158189 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,332 family providers in Virginia.

Other family in Blacksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →